New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of excipients (inactive ingredients) in drugs, […]
Shots: The DSMB has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. The recommendation was based on […]
Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts […]
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban […]
Shots: Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two […]
Shots: The P-ll RESTORE-1 study involves assessing NBIb-1817(VY-AADC) for the treatment of Parkinson’s disease. Neuroscience & Voyager will closely work with FDA & DCMB to […]
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the world health organization essential medicines […]
Shots: The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the […]
Shots: The updated label includes P-III DECLARE-TIMI 58 study that assesses the effect of Forxiga vs PBO on CV outcomes in 17000+ patients with T2D […]
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th Portfolio Management & Pipeline Optimization […]
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is […]
Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the […]
Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make […]
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie […]
The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it […]
Copyright © 2024 | WordPress Theme by MH Themes
